Abstract e Articoli Scientifici
Giancola ML, Balestra P, Ammassari A, Angeletti C, Ricottini M, Bellagamba R, Tommasi C, Gallo AL, Tempestilli M, Zaccarelli M, Lorenzini P, Pinnetti C, Narciso P, Antinori A, Nicastri E, and the ATAD study group. "Prevalence of neurocognitive impairment in a large cohort of HIV-positive patients on stable EFV/FTC/TDF regimen and relationship with plasmatic EFV levels and treatment adherence". Italian Conference on AIDS and Retroviruses, Riccione, 17-19 Maggio 2015. Oral presentation.
Pinnetti C, Libertone R, Balestra P, Lorenzini P, Ricottini M, Menichetti S, Plazzi M, Zaccarelli M, Ammassari A, Antinori A. "Declining prevalence of HIV-associated neurocognitive disorders in more recent years". Conference on Retroviruses and Opportunistic Infections_CROI, Seattle, 23-26 February 2015. Oral presentation.
Libertone R, Lorenzini P, Balestra P, Pinnetti C, Ricottini M, Plazzi MM, Menichetti S, Zaccarelli M, Nicastri E, Bellagamba R, Ammassari A, Antinori A. "Central nervous system penetration-effectiveness (CPE) rank does not reliably predict neurocognitive impairment in HIV-infected individuals". HIV Drug Therapy, Glasgow, 2-6 November 2014. Accepted as a poster.
Libertone R, Balestra P, Lorenzini P, Carmela P, Ricottini M, Menichetti S, Plazzi MM, Tozzi V, Antinori A, Ammassari A. “APRI and FIB-4 are not associated with neurocognitive impairment in HIV-infected persons”. HIV Drug Therapy, Glasgow, 2-6 November 2014.
Pinnetti C, Balestra P, Lorenzini P, Cozzi-Lepri A, Ricottini M, Ammassari A, Libertone R, Menichetti S, Tozzi V, Antinori A. "Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients". 20th International AIDS Conference, Melbourne, 20-25 July 2014. Oral presentation.
Giancola ML, Balestra P, Lorenzini P, Ricottini M, Gallo AL, Ascoli Bartoli T, Tommasi C, Nicastri E, Narciso P, Antinori A. "Analysis of the neurocognitive profile of a large cohort of HIV-positive patients on stable EFV/FTC/TDF regimen: relationship with pharmacokinetics of EFV". Italian Conference on AIDS and Retroviruses, Roma, 25-27 Maggio 2014. Accepted as a poster.
Libertone R, Balestra P, Lorenzini P, Carmela P, Ricottini M, Menichetti S, Plazzi MM, Tozzi V, Antinori A, Ammassari A. “APRI and FIB-4 are not associated with neurocognitive impairment in HIV-infected persons”. Italian Conference on AIDS and Retroviruses, Roma, 25-27
Maggio 2014. Oral presentation.
Pinnetti C, Balestra P, Ammassari A, Libertone R, Lorenzini P, Ricottini M, Plazzi M, Menichetti S, Tozzi V, Antinori A. "Cardiovascular Disease Framingham Risk Score (FRS) and VACS Index Are Associated with Neurocognitive Impairment (NCI) in HIV-positive Patients". 14th European AIDS Conference – EACS 2013. Accepted as a Best Poster Discussion presentation.
Libertone R, Ammassari A, Balestra P, Lorenzini P, Pinnetti C, Ricottini M, Menichetti S, Tozzi V, Antinori A. "Vitamin-D Deficiency is Associated with Higher Risk of Neurocognitive Impairment (NCI) in HIV-infected Persons". 14th European AIDS Conference – EACS 2013. Accepted as a poster.
Libertone R, Ammassari A, Balestra P, Lorenzini P, Pinnetti C, Ricottini M, Tozzi V, Antinori A. “Vitamin D deficiency is associated with higher risk of neurocognitive impairment in HIV-infected persons”. ICAR 2013 – Italian Conference on AIDS and Retroviruses, Torino, 12-14 Maggio 2013.
Antinori A, Balestra P, Lorenzini P, Libertone R, Cataldo G, D’Errico D, Pascucci T, Menichetti S, Ricottini M, Tozzi V. “Comparison of screening tools for the detection of neurocognitive impairment in HAART treated patients”. Eleventh International Congress on Drug Therapy in HIV Infection, 11-15 November 2012 Glasgow, UK.
Pubblicazioni a stampa
Tozzi V, Balestra P, Libertone R, Antinori A. Cognitive function in treated HIV patients. Neurobehavioral HIV Medicine 2010;2:95-113.
Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A. “Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders”. J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63.
Tozzi V., Balestra P, Vlassi C, Salvatori MF et al. Author's Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment". J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):657-8.
Tozzi V., Balestra P, Salvatori MF Authors' Response to Biscione: "Estimating the Risk of Persistent Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment".J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):510-2
Tozzi V., Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P “Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment: Prevalence and Risk Factors”.
J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82
Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7.
Tozzi V., Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P."Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART.” AIDS Res Hum Retroviruses. 2005 Aug;21(8):706-13.
Tozzi V., Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P ”Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.” J Neurovirol. 2005 Jul;11(3):265-73.
Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Fantoni M, Sampaolesi A, Noto P, Ippolito G, Wu AW.Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004 Apr;15(4):254-9.
Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Costa M, Sampaolesi A, Fantoni M, Noto P, Ippolito G, Wu AW. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses. 2003 Aug;19(8):643-52.
Tozzi V, Balestra P, Galgani S, Narcisop, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G. “Changes in Neurocognitive Performance in a Cohort of Patients Treated With HAART for 3 Years“ Journal of Acquired Immune Deficiency Syndromes 2001;28:19-27
Narciso P, Galgani S, Del Grosso B, De Marco M, De Santis A, Balestra P, Ciapparoni V, and Tozzi V, Acute disseminated encephalomyelitis as manifestation of primary HIV infection. Neurology 2001; 57: 1493-1496
Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D’Amato C, Affricano C, Pigorini F, Pau F M, De Felici A, Benedetto A “Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment” AIDS 1999, 13:1889-1897
Galgani S, Balestra P, Tozzi V, Narciso P, Ferri F, D’Amato C “Comparison of efficacy of different antiretroviral regimens on neuropsychological performance in HIV-1 patients”. Journal of Neurovirology, 1998; Vol 4, n.3, pg. 342
Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Pigorini F, D’Amato C “ Protease inhibitors based regimen and neuropsychological performance in HIV-1 patients. ”. Journal of Neurovirology, 1998; Vol 4, n.3, pg. 368
Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani ., D’amato, Pau FM, De Felici AP, Martini F, Benedetto A, Di Caro A, Affricano C “Regression of neurocognitive impairment with protease inhibitors based regimens” Reprinted from 12th Word AIDS Conference in Clinical Science, Monduzzi Editore; 1998, 2, 245-249.
Galgani S., Balestra P., Narciso P., Tozzi V., Pau F., Visco G. “Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1 associated cognitive deficits” AIDS, 1997, Vol. 11, pg. 1590-91
Galgani S, Balestra P, Zaccarelli M, Ferri F, Narciso p, Tozzi V, Pigorini F, Pau F, Visco G. “Neuropsychological performance and SPECT findings in a cohort of HIV positive patients” Journal of Neurovirology, 1996, Vol. 1, pg. 37.
Pigorini F, Rosci MA, Narciso P, Galgani S, Merigliano DE, Balestra P, Tozzi V, Pau FM. “Studio del flusso cerebrale mediante SPET in pazienti con infezione da HIV neurologicamente asintomatici. Valutazione in corso di trattamento con farmaci antiretrovirali” Convegno Annuale, Sottoprogetto 9 Studio di farmaci per l’AIDS, FATMA-CNR.
Balestra P, Galgani S, Zaccarelli M, Ferri F, Narciso P, Tozzi V, Pigorini F, Pau F, Visco G. “Attention Deficit and SPECT frontal lobe uptake defect in a cohort of HIV positive patients” Journal of Neurovirology, 1996, Vol. 1, pg. 31.
C. Blundo, P. Balestra, G. Borri, R. Gigli, A. Pingi, F Chiappetta “Utilità della correlazione morfofunzionale in neurochirurgia attraverso il metodo della localizzazione della lesione” XLIII Congresso della Società Italiana di Neurochirurgia , 1994 –Edizioni Minerva Medica – Torino.
Tozzi V, Narciso P., Galgani S, Sette P, Balestra P, et al. "Effects of Zidovudine on 30 patients with mild to and stage AIDS dementia complex" AIDS, 1993, 7, pp. 683-692.